BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34725458)

  • 21. Intratumoral PD-1
    Yu K; Gu Y; Zhang P; Fang H; Cao Y; Wang J; Lin C; Liu H; Zhang H; He H; Li R; Qin J; Li H; Xu J
    Br J Cancer; 2022 Nov; 127(9):1709-1717. PubMed ID: 36002752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103
    Li R; Liu H; Cao Y; Wang J; Chen Y; Qi Y; Lv K; Liu X; Yu K; Lin C; Zhang H; He H; Li H; Chen L; Shen Z; Qin J; Zhang W; Sun Y; Xu J
    Br J Cancer; 2020 May; 122(10):1525-1534. PubMed ID: 32205862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.
    Bu M; Shen Y; Seeger WL; An S; Qi R; Sanderson JA; Cai Y
    Tumour Biol; 2016 Mar; 37(3):3949-56. PubMed ID: 26482613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.
    Takano S; Saito H; Ikeguchi M
    Surg Today; 2016 Nov; 46(11):1341-7. PubMed ID: 26801344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and Preclinical Evaluation of
    Tao J; Zeng Z; He C; Meng L; Zhou W; Ren Y; Ma X; Wang Z; Liu J; Li D; Zhang Q; Zhao C; Yang Z; Zhu H
    Mol Pharm; 2024 Feb; 21(2):944-956. PubMed ID: 38270082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
    Romagnoli G; D'Alessandris QG; Capone I; Tavilla A; Canini I; Lapenta C; Buccarelli M; Giordano M; Tirelli V; Sanchez M; Fragale A; Giannetti S; Di Bonaventura R; Lauretti L; Biffoni M; Ricci-Vitiani L; Pallini R; Gabriele L
    Immunology; 2024 Feb; 171(2):198-211. PubMed ID: 37884280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
    Kandel S; Adhikary P; Li G; Cheng K
    Cancer Lett; 2021 Jul; 510():67-78. PubMed ID: 33895262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC.
    Ji J; Yin Y; Ju H; Xu X; Liu W; Fu Q; Hu J; Zhang X; Sun B
    Cell Death Dis; 2018 May; 9(5):478. PubMed ID: 29706626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TIM3 comes of age as an inhibitory receptor.
    Wolf Y; Anderson AC; Kuchroo VK
    Nat Rev Immunol; 2020 Mar; 20(3):173-185. PubMed ID: 31676858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.
    Liu JF; Wu L; Yang LL; Deng WW; Mao L; Wu H; Zhang WF; Sun ZJ
    J Exp Clin Cancer Res; 2018 Mar; 37(1):44. PubMed ID: 29506555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
    Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
    J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
    Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
    Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral TIGIT
    Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Trend of TIM3 Expression on T Cells in Patients With Nontuberculous Mycobacterial Lung Disease: From Immune Cell Dysfunction to Clinical Severity.
    Wang PH; Wu MF; Hsu CY; Pan SW; Shu CC; Cheng SL
    Front Immunol; 2021; 12():738056. PubMed ID: 34867961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8
    Tao J; Han D; Gao S; Zhang W; Yu H; Liu P; Fu R; Li L; Shao Z
    J Cell Mol Med; 2020 Jan; 24(1):1046-1058. PubMed ID: 31756785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between TIM3 Expression on Peripheral T Lymphocytes and Post-Stroke Depression.
    Mao Q; Zhang P; Qi W; Xia Y; Chen T; Li X; Xu S; Zhong Z; Shangguan Z
    Iran J Immunol; 2023 Dec; 20(4):427-437. PubMed ID: 38102856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral CD103
    Gu Y; Chen Y; Jin K; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
    Oncoimmunology; 2020 Nov; 9(1):1844402. PubMed ID: 33312758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8
    Li R; Zhang H; Cao Y; Liu X; Chen Y; Qi Y; Wang J; Yu K; Lin C; Liu H; He H; Li H; Chen L; Shen Z; Qin J; Zhang W; Sun Y; Xu J
    Cancer Immunol Immunother; 2020 Jul; 69(7):1327-1336. PubMed ID: 32200421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.